Compare ASTRAZENECA PHARMA with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ASTRAZENECA PHARMA vs GSK PHARMA - Comparison Results

ASTRAZENECA PHARMA     Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ASTRAZENECA PHARMA GSK PHARMA ASTRAZENECA PHARMA/
GSK PHARMA
 
P/E (TTM) x 91.6 31.7 288.8% View Chart
P/BV x 25.8 12.6 204.2% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 ASTRAZENECA PHARMA   GSK PHARMA
EQUITY SHARE DATA
    ASTRAZENECA PHARMA
Mar-18
GSK PHARMA
Mar-19
ASTRAZENECA PHARMA/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,2783,595 35.5%   
Low Rs8831,253 70.4%   
Sales per share (Unadj.) Rs228.4184.7 123.7%  
Earnings per share (Unadj.) Rs10.426.3 39.4%  
Cash flow per share (Unadj.) Rs16.329.2 55.8%  
Dividends per share (Unadj.) Rs020.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs98.8126.3 78.2%  
Shares outstanding (eoy) m25.00169.40 14.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.713.1 36.0%   
Avg P/E ratio x104.292.2 113.1%  
P/CF ratio (eoy) x66.483.1 79.9%  
Price / Book Value ratio x10.919.2 57.0%  
Dividend payout %076.1 0.0%   
Avg Mkt Cap Rs m27,008410,626 6.6%   
No. of employees `0001.45.0 27.3%   
Total wages/salary Rs m1,5355,372 28.6%   
Avg. sales/employee Rs Th4,210.96,306.7 66.8%   
Avg. wages/employee Rs Th1,132.21,083.1 104.5%   
Avg. net profit/employee Rs Th191.1898.0 21.3%   
INCOME DATA
Net Sales Rs m5,71031,281 18.3%  
Other income Rs m1231,023 12.0%   
Total revenues Rs m5,83332,304 18.1%   
Gross profit Rs m4636,009 7.7%  
Depreciation Rs m147486 30.3%   
Interest Rs m06 0.0%   
Profit before tax Rs m4386,540 6.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m1792,373 7.5%   
Profit after tax Rs m2594,454 5.8%  
Gross profit margin %8.119.2 42.2%  
Effective tax rate %40.836.3 112.6%   
Net profit margin %4.514.2 31.9%  
BALANCE SHEET DATA
Current assets Rs m3,20920,061 16.0%   
Current liabilities Rs m2,07014,543 14.2%   
Net working cap to sales %20.017.6 113.1%  
Current ratio x1.61.4 112.4%  
Inventory Days Days7257 127.4%  
Debtors Days Days3514 248.4%  
Net fixed assets Rs m79014,343 5.5%   
Share capital Rs m501,694 3.0%   
"Free" reserves Rs m2,41919,704 12.3%   
Net worth Rs m2,46921,398 11.5%   
Long term debt Rs m02 0.0%   
Total assets Rs m4,60539,113 11.8%  
Interest coverage xNM1,091.0-  
Debt to equity ratio x00 0.0%  
Sales to assets ratio x1.20.8 155.0%   
Return on assets %5.611.4 49.3%  
Return on equity %10.520.8 50.4%  
Return on capital %17.731.9 55.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m300534 56.1%   
Fx outflow Rs m2,0157,091 28.4%   
Net fx Rs m-1,715-6,557 26.2%   
CASH FLOW
From Operations Rs m883,994 2.2%  
From Investments Rs m-94-1,433 6.5%  
From Financial Activity Rs mNA-3,584 0.0%  
Net Cashflow Rs m-6-1,023 0.6%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 75.0 50.7 147.9%  
Indian inst/Mut Fund % 0.3 10.2 2.9%  
FIIs % 15.7 23.8 66.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 15.4 59.1%  
Shareholders   12,856 102,036 12.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ASTRAZENECA PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  VENUS REMEDIES  

Compare ASTRAZENECA PHARMA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 229 Points Lower; Banking and Metal Stocks Witness Selling(Closing)

Indian share markets fell sharply during closing hours today amid weak global cues and disappointing domestic factory output data.

Related Views on News

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ASTRAZENECA PHARMA SHARE PRICE


Nov 13, 2019 03:37 PM

TRACK ASTRAZENECA PHARMA

  • Track your investment in ASTRAZENECA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ASTRAZENECA PHARMA

ASTRAZENECA PHARMA 8-QTR ANALYSIS

COMPARE ASTRAZENECA PHARMA WITH

MARKET STATS